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Abstract
Background: Doppler ultrasonography (US) is increasingly being utilized as an imaging modality
in breast cancer. It is used to study the vascular characteristics of the tumor. Neoadjuvant
chemotherapy is the standard modality of treatment in locally advanced breast cancer. Histological
examination remains the gold standard to assess the chemotherapy response. However, based on
the color Doppler findings, a new scoring system that could predict histological response following
chemotherapy is proposed.
Methods: Fifty cases of locally advanced infiltrating duct carcinoma of the breast were studied. The
mean age of the patients was 44.5 years. All patients underwent clinical, Doppler and
histopathological assessment followed by three cycles of CAF (Cyclophosphamide, Adriamycin and
5-Fluorouracil) chemotherapy, repeat clinical and Doppler examination and surgery. The resected
specimens were examined histopathologically and histological response was correlated with
Doppler findings. The Doppler characteristics of the tumor were graded as 1–4 for <25%, 25–50%,
>50% and complete disappearance of flow signals respectively. A cumulative score was calculated
and compared with histopathological response. Results were analyzed using Chi square test,
sensitivity, specificity, positive and negative predictive values.
Results: The maximum Doppler score according to the proposed scoring system was twelve and
minimum three. Higher scores corresponded with a more favorable histopathological response.
Twenty four patients had complete response to chemotherapy. Sixteen of these 24 patients
(66.7%) had a cumulative Doppler score more than nine. The sensitivity of cumulative score >5 was
91.7% and specificity was 38.5%. The area under the ROC curve of the cumulative score >9 was
0.72.
Conclusion: Doppler scoring can be accurately used to objectively predict the response to
chemotherapy in patients with locally advanced breast cancer and it correlates well with
histopathological response.
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Background
Breast cancer is a leading cause of death in women. In
spite of advances in treatment, mortality in this subset of
patients is substantial. An advanced local disease in the
form of extensive edema of skin, ulceration, large lump
and fixity limit the applicability of local treatment alone.
Neoadjuvant chemotherapy has been accepted as the pri-
mary modality of treatment in locally advanced breast
cancer. It offers a definite advantage by down staging the
tumor thus allowing less extensive surgery. It also
improves survival in chemo-responsive patients and pro-
vides better quality of life. Chemo-responsive tumors
have a better overall survival than non-responders [1]. It
is imperative to evaluate the response to chemotherapy
objectively. Imaging modalities like mammography,
ultrasound, computed tomography, magnetic resonance
imaging and radioisotopes are used for evaluation of
breast [2,3]. Ultrasonography (US) is used primarily for
diagnostic purposes and for wire localization biopsy of
atypical or suspicious lesions. With the technological
advances in sonographic imaging, US can now be used as
an alternative method for assessment of the tumor includ-
ing the response to primary systemic treatment [4]. Color
Doppler is also used in the assessment of tumor vascular-
ity since it can detect vessels as small as 0.2 mm in diam-
eter [5]. The Doppler Sonographic study of vascularity
includes assessment of parameters like number of flow
signals, peak flow velocity (Vmax), resistivity index (RI),
and pulsatility index (PI). It also permits noninvasive vis-
ualization of abnormal vessel architecture in breast
tumors referred to as neoangiogenesis. The change in vas-
cularity of the tumor corresponds to the histopathological
response and therefore the study of vascularity can be
used as an objective complementary tool for assessing
response to therapy in locally advanced breast cancer. The
purpose of this study was to propose a Doppler scoring
system which would provide a quantitative method of
assessment and predict the response which would help in
monitoring primary chemotherapy in locally advanced
breast cancer and prognosis.
Patients and methods
This prospective clinical study included 50 patients with
locally advanced breast cancer who received neo-adjuvant
chemotherapy in a single surgical unit at a tertiary level
university teaching hospital in North India between Janu-
ary 2001 and January 2005. The Institute postgraduate
research board and the departmental research committee
have approved the study and the informed written con-
sent of the subjects was recorded individually on the case
records. The included patients had T3 or T4 lesions with
positive histology. Patients were evaluated clinically prior
to chemotherapy and surgery. They received 3 cycles of
neoadjuvant chemotherapy (a combination of Cyclo-
phosphamide, Adriamycin and 5-Fluorouracil) at three
weekly intervals prior to mastectomy which was per-
formed in all patients. Color Doppler examination of the
tumor was done using LOGIQ 400 CL System (GE medi-
cal system) with a LA 39, 11 MHz probe and the parame-
ters were recorded. Ultrasound examination was
performed by a single experienced sonologist who was
blinded to the patients' clinical profile, treatment history,
response status and the pre chemotherapy findings. The
scan was done in multiple planes to include whole of the
breast and axilla. Standardised machine setting were used
to optimise sensitivity to low velocity and low volume
blood flow. The Doppler scan was done to evaluate intra-
tumoral flow signals, PI i.e. Peak flow velocity - End
diastolic velocity/average velocity, RI  i.e. Peak systolic
velocity - End diastolic velocity/Peak systolic velocity and
Vmax. The number of flow signals was assessed manually
by counting the pixels inside the tumor mass. Tumor
response evaluation was done as per the RECIST guide-
lines [6]. The Doppler findings were graded as 1–4 and the
grading was done with reference to the Doppler assessable
parameters (Percentage change in RI, PI & Vmax) individ-
ually: Grade 1 – Increase/no change/less than 25% reduc-
tion (given score-1); Grade 2 – 25–50% reduction (given
score-2); Grade 3 – More than 50% reduction but not
complete disappearance (given score-3); Grade 4 – Com-
plete disappearance (given score-4). Histopathological
response grading was done as: Grade 1 – No chemothera-
peutic change; Grade 2 – Minimal chemotherapeutic
change (<50%); Grade 3 – Moderate chemotherapeutic
change (>50% but <100%); Grade 4 – Complete annihi-
lation of tumor (100% disappearance of tumor). The indi-
vidual grades of RI, PI & Vmax for a patient were added
and the cumulative scores were evaluated at different cut
off points, i.e. >5, >7 and >9. The sensitivity, specificity,
PPV, NPV were calculated at different Grades, i.e. >1, >2 &
>3 of RI, PI & Vmax and compared to histopathology
grade 4 which was taken as the gold standard. Chi square
test (χ2) was also used for analysis of results. ROC curves
were obtained for the RI, PI, Vmax scores individually and
also for the cumulative score of the Doppler parameters.
Results
The mean age of patients was 44.5 years, ranging from 30–
65 years. The mean clinical diameter of the breast mass
was 8.4 cm (range 6.7–14.6 cm). Forty four (88%) had T4b
lesion at presentation. All patients showed the presence of
hyper-vascular signals on pre-therapy color Doppler US.
Complete response was seen in 24(48%) patients who
could be correlated histologically. PI, RI and Vmax could
not be measured in patients who had complete regression
of the tumor. The grades of response in Doppler parame-
ters following chemotherapy is shown in Table-1. Twenty
two (44%) and 18(36%) of the 50 patients showed regres-
sion in RI and PI respectively while 4 (8%) and 8 (16%)
patients respectively had increase in these parameters.World Journal of Surgical Oncology 2007, 5:99 http://www.wjso.com/content/5/1/99
Page 3 of 6
(page number not for citation purposes)
Degree of changes in respect of RI, PI, Vmax varied accord-
ing to grades of response. The mean measured values of
PI, RI and Vmax at the time of presentation were 0.756 ±
0.246, 1.358 ± 0.546 and 0.396 ± 0.294 m/sec respec-
tively. The cumulative Doppler scores were correlated
with histopathological grades of response and found to be
statistically significant (p < 0.05) (Table-2). Figures-1 and
2 show changes in color Doppler and Figure-3 shows a
complete clinical response. The sensitivity and specificity
at cumulative score >5 was 91.7% and 38.5% respectively.
RI, PI & Vmax grade >3 and cumulative score >9 had the
same values of diagnostic measures (Table-3). The ROC
curves of RI, PI, Vmax at grade >3 (Figure-4) have the same
area under the curve of 0.72. The ROC curve for the cumu-
lative score of >5, >7 and >9 are shown in Figure-5. The
area under the ROC curve of the cumulative score >9 is
0.72. These diagnostic tests are fair because the area under
the curves lie between 0.7 to 0.8.
Discussion
Breast carcinoma significantly influences the women's
health and is assuming greater importance in the develop-
ing countries due to the rising incidence, delay in presen-
tation and dismal outcome. The advances in imaging
modalities are not affordable to the financially compro-
mised patients. Neoadjuvant chemotherapy offers a defi-
nite advantage by down staging the tumor, allowing less
extensive surgery, controlling local and distant recurrence
and providing a better quality of life. A steady decline in
the mortality and increase in overall survival rates because
of multimodality treatment is being contemplated in
developing countries.
Rational use of neoadjuvant chemotherapy requires
objective evaluation of chemotherapeutic response.
Response assessment also helps in determining the early
termination of ineffective regimens and change in the
chemotherapeutic regimen [7]. The methods available are
able to assess the response but predictability in an individ-
ual patient has not been documented. Various scoring sys-
tems have been advocated in breast cancer [5,8].
However, none of these are helpful in locally advanced
carcinoma and can not predict chemotherapeutic
response in patients undergoing neoadjuvant chemother-
apy. This aspect has not been studied in available litera-
ture. An assessment of additional methods that identify
changes in tumor physiology and vascularity were used
for developing the proposed scoring system. Further, to
assess the tumor behavior and response following ther-
apy, a combination of two or more objective parameters
must complement physical examination findings. The
sensitivity of clinical examination alone for predicting
pathological response was only 44.44% in one study [4].
Use of US as a response assessment tool has both objectiv-
ity and reproducibility. Vallone P et al [9] have concluded
that ultrasound is the first step in assessing the efficacy of
neoadjuvant chemotherapy in patients with locally
advanced breast carcinoma.
Three dimensional tumor localization is better with
sonography as it excludes the cutaneous edema. Dynamic
magnetic resonance mammography and scintimammog-
raphy have been used to assess the residual disease follow-
ing chemotherapy [7,10,11]. However, these methods are
not cost effective in developing countries. Color Doppler
Complete tumor disappearance on color Doppler Figure 2
Complete tumor disappearance on color Doppler.
Table 1: Grades of response in Doppler parameters following 
chemotherapy
Grades 
of 
response
RI
No. of patients (%)
PI
No. of patients (%)
Vmax
No. of patients 
(%)
1 22 (44%)* 18 (36%)** 2 (4%)
2 4 (8%) 6 (12%) 12 (24%)
3 0 2 (4%) 12 (24%)
4 24 (48%) 24 (48%) 24 (48%)
* 4 patients showed increase in RI, ** 8 showed increase in PI
Partial tumor disappearance on color Doppler Figure 1
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can be used to accurately measure the tumor vascularity
changes following chemotherapy [12]. Contrary to
dynamic MRI mammography, color Doppler is cost effec-
tive and easily accessible. The present study emphasizes its
predictive value in response assessment against histopa-
thology which is gold standard. The various parameters in
a color Doppler study, besides the tumor size, are RI, PI,
and Vmax. The RI has been found to be higher in malig-
nant masses with sensitivity of up to 95.5% [13]. RI how-
ever depends on the presence of color flow in the tumor
mass, and hence cannot be used as an independent pre-
dictor for response. The PI showed variable changes fol-
lowing chemotherapy. It was also dependent on the
presence of flow signals in the tumor. Flow signals disap-
peared in patients with complete response. Correspond-
ing changes in RI and PI have also been anticipated and
confirmed in this study. All these color Doppler parame-
ters put together can be used to assess independently the
response of chemotherapy in breast cancer. Roubidoux et
al [14], sonographically evaluated early stage breast cancer
in 34 patients undergoing neoadjuvant chemotherapy
and documented that the vascularity decreased following
chemotherapy and was not specific for complete
response. However, the present study observed that color
Doppler is an independent predictor of chemotherapeutic
response for locally advanced breast carcinoma. The gold
standard for assessing response is histological changes in
the form of histiocytosis, stromal fibrosis, calcification
and lymphocytic infiltration. Since histopathological
response is assessed in the postoperative specimen, color
Doppler is an appropriate tool for pre-surgical assessment
that correlates with the histopathological changes. We
propose through this study a scoring system based on the
different color Doppler parameters which would predict
histopathological response in patients undergoing neoad-
juvant chemotherapy. A score of more than 9 suggests a
good response and less than 5 a poor response. A higher
score showed statistically significant correlation with a
histopathological response.
The objectives of the study were to evaluate the primary
tumor mass only and formulate a scoring system based on
primary tumor response assessed by color Doppler. The
axillary lymph node status before or after induction chem-
otherapy has not been included in the present study.
However, the study recommends further evaluation and
correlation with response to chemotherapy of non-senti-
nel lymph nodes. Some independent parameters like ER,
PR, erb-2/neu, VEGF etc. may predict response to induc-
tion chemotherapy and need correlation and could be
another component of study. This being a pilot study with
Clinical photograph of the patient Figure 3
Clinical photograph of the patient.
Table 2: Histological response and Doppler cumulative score
Cumulative score of Doppler indices
Histological response 3–5
No. of patients (%)
6–9
No. of patients (%)
10–12
No. of patients (%)
Total
2 4(8%) 2(4%) 2(4%) 8(16%)
3 6(12%) 8(16%) 4(8%) 18(36%)
4 2(4%) 6(12%) 16(32%) 24(48%)
Total 12(24%) 16(32%) 22(44%) 50(100%)
X2 = 12.12, p < 0.05. Grade-1 response was not observed in any patient
Table 3: Comparison of Clinical, sonographic and Doppler 
response
Modality Sensi
tivity 
(%)
Speci
ficity 
(%)
PPV 
(%)
NPV 
(%)
Clinical 45.8 92.3 84.6 64.9
USG 33.3 88.5 72.7 59.0
Cummulative color Doppler 
score
>5 91.7 38.5 57.9 83.3
>7 66.7 61.5 61.5 66.7
>9 66.7 76.9 72.7 71.4
RI score >1 91.7 53.8 64.7 87.5
>2 66.7 69.2 66.7 69.2
>3 66.7 76.9 72.7 71.4
PI score >1 83.3 38.5 55.6 71.4
>2 66.7 61.5 61.5 66.7
>3 66.7 76.9 72.7 71.4
Vmax score >1 100 7.7 50.0 100
>2 91.7 38.5 57.9 83.3
>3 66.7 76.5 72.7 71.4World Journal of Surgical Oncology 2007, 5:99 http://www.wjso.com/content/5/1/99
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a view to suggest a scoring system based on color Doppler
to assess response in the primary tumor, would act as a
guide for further study.
The present study highlights the use of a cheaper modality
to predict and monitor the response of advanced breast
cancer to neoadjuvant chemotherapy. This is especially
the need in the developing or third world countries where
the cost of treatment is to be contained. By avoiding inef-
fective chemotherapy and reducing advanced surgery, the
treatment will be more cost-effective in cases where the
overall outlook is intrinsically bad. Color Doppler is an
important and promising alternative to more expensive
investigations. Multicenteric studies with longer follow-
up periods will be required to establish this scoring system
as a powerful tool in predicting the response and will have
important therapeutic implications.
Conclusion
Study of color Doppler vascularity changes in breast can-
cer directly correlates with histological response. Doppler
scoring can be accurately used to objectively predict the
response to chemotherapy in patients with locally
advanced breast cancer. Higher score corresponded with a
positive histological response. In the present study, forty
four percent cases with complete response to chemother-
apy had a score more than nine (p < 0.05). The sensitivity
and specificity of the Doppler scoring, NPV and PPV in the
study further supports the response assessment criteria.
The scoring system suggested in the present study can pre-
dict the histopathological response in patients undergo-
ing neoadjuvant chemotherapy.
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